evolocumabalirocumabtertiary hospital
…Background and Importance PCSK9 inhibitors (alirocumab and evolocumab) effectively reduce Low-density lipoprotein (LDLc) and cardiova…
7articles mentioning drugs
20drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Alirocumab ×
Alirocumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Alirocumab
7 articles · page 1 of 1bempedoic acidicosapent ethylevolocumabinclisiranalirocumab
…th the greatest reductions in LDL-C, followed by inclisiran and bempedoic acid.…
evolocumabezetimibeevolucumabalirocumabrosuvastatinatorvastatinsecondary cardiovascular events or strokes
…ilisin/kexin type 9 inhibitors (PCSK9i), such as alirocumab and evolocumab, effectively manage cLDL levels. However, the relative efficacy…
99.1%
inclisiranevolocumabalirocumabatorvastatinrosuvastatinperipheral arterial diseaseischaemic heart diseaseischaemic cerebrovascular diseaseheterozygous familial hypercholesterolaemiaHeFH+2 more
…itors (PCSK9 inhibitors), including evolocumab, alirocumab, and inclisiran, are potent lipid-lowering agents indicated for patients at hig…
evolocumabalirocumabPCSK9iezetimibebempedoic acidhypercholesterolaemiatertiary care hospital
…s with hypercholesterolaemia treated with PCSK9i (alirocumab or evolocumab).To assess the acceptance rate of the interventions.Material an…
inclisiranalirocumabezetimibeevolocumabfenofibratestatinbempedoic acidischaemic heart diseaseprimary hypercholesterolaemia
…isease, and three with familial hypercholesterolaemia. Prior to inclisiran, 11 patients (28.9%) had been treated with evolocumab and 2 pat…
inclisiranevolocumabalirocumabbococizumabtafolecimabPCSK9iatherosclerotic cardiovascular diseaseFamilial hypercholesterolaemia (FH)
… including alirocumab, bococizumab, evolocumab, tafolecimab and inclisiran. Eligible studies reported changes in LDL-C, apolipoprotein B (…